TORO: Ninety-Six-Week Virologic and Immunologic Response and Safety Evaluation of Enfuvirtide with an Optimized Background of Antiretrovirals
- 1 August 2007
- journal article
- research article
- Published by Mary Ann Liebert Inc in AIDS Patient Care and STDs
- Vol. 21 (8), 533-543
- https://doi.org/10.1089/apc.2006.0174
Abstract
The additional 48-week optional treatment extension of the T-20 versus Optimized Regimen Only (TORO) studies evaluated long-term safety and efficacy of enfuvirtide (ENF) through week 96 in patients receiving ENF plus optimized background (OB) and patients switching to ENF plus OB from OB alone. Patient randomization was 2:1 to ENF plus OB (n = 663) and OB (n = 334), of which 89.7% and 89.8% were male, 89.3% and 88.6% were Caucasian, and median age was 41 and 42 years, respectively. HIV risk factors were comparable between the ENF plus OB and OB groups with the major factors being 65.2% versus 66.2% homosexual contact, 17.8% versus 19.8% heterosexual contact, 4.1% versus 4.8% bisexual contact, respectively, and 6.9% injection drug use in both groups. OB patients were allowed to switch to ENF plus OB at virologic failure before week 48 and required to switch at week 48 to continue in the study (n = 230). Efficacy and safety assessments were conducted for each group. At week 96, 55% of ENF plus OB subjects completed the study and 26.5% achieved a viral load of less than 400 copies per milliliter (17.5% achieved less than 50 copies per milliliter). Viral load and CD4 mean change from baseline was −2.1 and −1.1 log10 HIV-1-RNA copies per milliliter and +166 and +116 CD4 cells/mm3 for ENF plus OB and switch patients, respectively. No new ENF-related safety issues emerged in weeks 48–96. Injection site reactions led to discontinuation in 7% and 10% of ENF plus OB and switch patients, respectively. In conclusion, these data demonstrate durable efficacy and safety of ENF over 96 weeks and that early use of ENF in combination with other agents for the treatment of antiretroviral-experienced HIV-infected subjects is beneficial.Keywords
This publication has 24 references indexed in Scilit:
- Week-12 Response to Therapy as a Predictor of Week 24, 48, and 96 Outcome in Patients Receiving the HIV Fusion Inhibitor Enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) TrialsClinical Infectious Diseases, 2006
- Cost-Effectiveness of Enfuvirtide in HIV Therapy for Treatment-Experienced Patients in the United StatesAIDS Research and Human Retroviruses, 2006
- Prognostic Staging of Extensively Pretreated Patients with Advanced HIV-1 DiseaseHIV Research & Clinical Practice, 2005
- CD4+Cell Count Increase Predicts Clinical Benefits in Patients with Advanced HIV Disease and Persistent Viremia after 1 Year of Combination Antiretroviral TherapyThe Journal of Infectious Diseases, 2005
- Compromised Immunologic Recovery in Treatment-Experienced Patients with HIV Infection Receiving Both Tenofovir Disoproxil Fumarate and Didanosine in the TORO StudiesClinical Infectious Diseases, 2005
- HIV‐1 Drug Resistance: Degree of Underestimation by a Cross‐Sectional versus a Longitudinal Testing ApproachThe Journal of Infectious Diseases, 2005
- Cost-Effectiveness of Enfuvirtide for Treatment-Experienced Patients with HIV in ItalyHIV Research & Clinical Practice, 2005
- Clinical perspective of fusion inhibitors for treatment of HIVJournal of Antimicrobial Chemotherapy, 2004
- Patient Acceptance of Self-Injected Enfuvirtide at 8 and 24 WeeksHIV Research & Clinical Practice, 2003
- Long-Term Treatment with Subcutaneous T-20, a Fusion Inhibitor, in HIV-Infected Patients: Patient Satisfaction and Impact on Activities of Daily LivingAIDS Patient Care and STDs, 2002